ES2596435T3 - Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia - Google Patents
Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia Download PDFInfo
- Publication number
- ES2596435T3 ES2596435T3 ES13181216.6T ES13181216T ES2596435T3 ES 2596435 T3 ES2596435 T3 ES 2596435T3 ES 13181216 T ES13181216 T ES 13181216T ES 2596435 T3 ES2596435 T3 ES 2596435T3
- Authority
- ES
- Spain
- Prior art keywords
- day
- desmopressin
- subjects
- nocturnal
- placebo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract description 35
- 229960004281 desmopressin Drugs 0.000 title abstract description 35
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract description 35
- 206010029446 nocturia Diseases 0.000 title abstract description 15
- 230000000422 nocturnal effect Effects 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000012458 free base Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 36
- 229940068196 placebo Drugs 0.000 description 36
- 230000008859 change Effects 0.000 description 27
- 210000002700 urine Anatomy 0.000 description 23
- 230000009467 reduction Effects 0.000 description 17
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 16
- 229910052708 sodium Inorganic materials 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 230000007423 decrease Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000004622 sleep time Effects 0.000 description 9
- 206010021036 Hyponatraemia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004617 sleep duration Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000003860 sleep quality Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5512008P | 2008-05-21 | 2008-05-21 | |
| US55120P | 2008-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2596435T3 true ES2596435T3 (es) | 2017-01-09 |
Family
ID=41100519
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13181216.6T Active ES2596435T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES17171155T Active ES2756706T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
| ES16165875.2T Active ES2677548T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES09751584.5T Active ES2462465T5 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia |
| ES17171152T Active ES2710454T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17171155T Active ES2756706T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
| ES16165875.2T Active ES2677548T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia |
| ES09751584.5T Active ES2462465T5 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial del sueño no alterado por nocturia |
| ES17171152T Active ES2710454T3 (es) | 2008-05-21 | 2009-05-21 | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nocturia |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9974826B2 (2) |
| EP (5) | EP3225250B1 (2) |
| JP (5) | JP5767103B2 (2) |
| CA (1) | CA2724653A1 (2) |
| DK (5) | DK2712622T3 (2) |
| ES (5) | ES2596435T3 (2) |
| HR (4) | HRP20161066T1 (2) |
| HU (5) | HUE039013T4 (2) |
| LT (5) | LT3085381T (2) |
| LU (1) | LUC00015I2 (2) |
| NO (3) | NO3085381T3 (2) |
| PL (5) | PL2296686T5 (2) |
| PT (5) | PT3225249T (2) |
| SI (4) | SI3225250T1 (2) |
| TR (2) | TR201807224T4 (2) |
| WO (1) | WO2009143356A1 (2) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20100286045A1 (en) * | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| NO3085381T3 (2) * | 2008-05-21 | 2018-09-15 | ||
| WO2015063602A1 (en) * | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
| EP3868215A4 (en) * | 2018-10-16 | 2022-07-27 | Nippon Chemiphar Co., Ltd. | SLEEP QUALITY IMPROVING AGENT |
| US20210393562A1 (en) * | 2018-10-17 | 2021-12-23 | Nippon Chemiphar Co., Ltd. | Therapeutic or prophylactic agent for nocturnal polyuria |
| US20230149330A1 (en) * | 2020-04-14 | 2023-05-18 | Nippon Chemiphar Co., Ltd. | Sleep quality improver |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4285858A (en) | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
| ATE24964T1 (de) | 1981-12-11 | 1987-01-15 | Wyeth John & Brother Ltd | Verfahren zur herstellung von festen formgegenstaenden. |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| DK365389D0 (da) | 1989-07-24 | 1989-07-24 | Fertin Lab As | Antifungalt tyggegummipraeparat |
| US5091186A (en) | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| TW279133B (2) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| SE9101022D0 (sv) | 1991-01-09 | 1991-04-08 | Paal Svedman | Medicinsk suganordning |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| DE69231536T2 (de) | 1991-08-26 | 2001-06-13 | Abbott Laboratories, Abbott Park | Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien |
| US5466464A (en) | 1991-12-24 | 1995-11-14 | Yamanouchi Pharmaceutical Co., Ltd. | Intrabuccally disintegrating preparation and production thereof |
| US5298256A (en) | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| US5434121A (en) * | 1993-03-25 | 1995-07-18 | Mitsui Toatsu Chemicals, Incorporated | Variety of Drechslera monoceras, weed control compositions containing the same as an effective ingredient and weed control methods using the same |
| SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
| RU2135204C1 (ru) | 1993-06-29 | 1999-08-27 | Ферринг Б.В. | Составы для назального введения десмопрессина |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| US5500413A (en) | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5674850A (en) | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
| DK0710243T3 (da) | 1993-06-29 | 2000-10-16 | Ferring Bv | Syntese af cykliske peptider |
| AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| US5611806A (en) | 1994-05-23 | 1997-03-18 | Samsung Electro-Mechanics Co., Ltd. | Skin perforating device for transdermal medication |
| DE4424800A1 (de) * | 1994-07-14 | 1996-01-18 | Philips Patentverwaltung | Schaltungsanordnung zum Liefern von Speisespannungen |
| SE518619C2 (sv) | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| TW411277B (en) | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| EP0914178B1 (en) | 1996-06-18 | 2003-03-12 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
| US5763398A (en) | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| FR2758195B1 (fr) | 1997-01-09 | 1999-02-26 | Sgs Thomson Microelectronics | Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US6194407B1 (en) | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
| US6511974B1 (en) | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| US5932745A (en) | 1997-07-30 | 1999-08-03 | American Home Products Corporation | Process for converting propargylic amine-N-oxides to enaminones |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| US6090803A (en) | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
| US6406455B1 (en) | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US20060025387A1 (en) | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| US6297234B1 (en) | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
| US6344451B1 (en) | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| US6235900B1 (en) | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
| US6620807B1 (en) | 1999-02-04 | 2003-09-16 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| EP1153616B1 (en) | 1999-02-15 | 2004-12-01 | Sumitomo Pharmaceuticals Company, Limited | Tablets quickly disintegrated in the oral cavity |
| JP2002537031A (ja) | 1999-02-18 | 2002-11-05 | バイオバルブ テクノロジーズ インコーポレイテッド | 電気活性な細孔 |
| AR014640A1 (es) | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| WO2001051109A1 (en) | 2000-01-07 | 2001-07-19 | Biovalve Technologies, Inc. | Injection device |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| TWI287984B (en) | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
| BR0114909A (pt) | 2000-10-26 | 2004-02-03 | Alza Corp | Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas |
| ES2717656T3 (es) | 2000-11-30 | 2019-06-24 | Valeritas Inc | Dispositivo con microsonda amovible sustancialmente libre sobre el alojamiento |
| KR20030071780A (ko) | 2000-11-30 | 2003-09-06 | 바이오밸브 테크놀로지스, 인코포레이티드 | 주입기 |
| US9302903B2 (en) | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| WO2002050584A2 (en) | 2000-12-21 | 2002-06-27 | Biovalve Technologies, Inc. | Microneedle array systems |
| ATE364380T1 (de) | 2001-03-16 | 2007-07-15 | Alza Corp | Transdermales pflaster zur verabreichung von fentanyl |
| US7053083B2 (en) | 2001-04-12 | 2006-05-30 | Wyeth | Cyclohexylphenyl vasopressin agonists |
| JP2004530668A (ja) | 2001-04-12 | 2004-10-07 | ワイス | バソプレッシンアゴニストとしてのｎ−ビフェニルカルボニル−およびｎ−フェニルピリジルカルボニル置換二および三環アゼピンおよびジアゼピン |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| US7615234B2 (en) | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| GB2391480B (en) | 2002-08-05 | 2007-02-28 | Caretek Medical Ltd | Drug delivery system |
| MXPA04002449A (es) | 2001-09-13 | 2004-07-23 | Kissei Pharmaceutical | Cristales de derivado de hidroxinorefedrina. |
| US6723077B2 (en) | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| AU2002349773B2 (en) | 2001-11-16 | 2007-12-13 | Astellas Pharma Inc. | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| HRP20041152B1 (hr) | 2002-05-07 | 2008-01-31 | Ferring B.V. | Farmaceutske formulacije |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| US20040115167A1 (en) | 2002-09-30 | 2004-06-17 | Michel Cormier | Drug delivery device and method having coated microprojections incorporating vasoconstrictors |
| HK1079786B (zh) | 2002-10-09 | 2010-03-12 | 东丽株式会社 | 尿频或尿失禁的治疗或预防剂以及具有含氮环状取代基的吗啡烷衍生物 |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| DE10259934B3 (de) | 2002-12-20 | 2004-10-14 | H.C. Starck Gmbh | Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1619185B1 (en) | 2003-04-28 | 2011-06-15 | Astellas Pharma Inc. | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| PL1638468T3 (pl) | 2003-06-30 | 2008-01-31 | Alza Corp | Sposób powlekania mikrowystępów do przekłuwania skóry |
| CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| ATE301990T1 (de) | 2003-07-25 | 2005-09-15 | Ferring Bv | Pharmazeutische desmopressin-zubereitung als feste darreichungsform und methode zu ihrer herstellung |
| US6930932B2 (en) | 2003-08-27 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Data signal reception latch control using clock aligned relative to strobe signal |
| CN1897899A (zh) | 2003-10-24 | 2007-01-17 | 阿尔扎公司 | 促进透皮药物传递的装置和方法 |
| EP1675539A4 (en) | 2003-10-24 | 2007-09-12 | Alza Corp | METHOD AND SYSTEM FOR PRETREATMENT FOR IMPROVING TRANSDERMAL DRUG DELIVERY |
| CA2543641A1 (en) | 2003-10-31 | 2005-05-19 | Alza Corporation | Self-actuating applicator for microprojection array |
| EP2322196A2 (en) * | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
| DK1530967T3 (da) | 2003-11-13 | 2006-07-03 | Ferring Bv | Blisterpakning og dertil hörende fast dosisform |
| ATE319430T1 (de) | 2003-12-29 | 2006-03-15 | Ferring Bv | Verfahren zur herstellung einer festen oralen dosierungsform von desmopressin |
| US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| JP2007519446A (ja) | 2004-01-09 | 2007-07-19 | アルザ・コーポレーシヨン | 振動支援型の経皮的な薬剤の送達法および系 |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US7097776B2 (en) | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
| US20060093658A1 (en) | 2004-10-26 | 2006-05-04 | Gayatri Sathyan | Apparatus and method for transdermal delivery of desmopressin |
| CN100339081C (zh) | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| US7180274B2 (en) | 2004-12-10 | 2007-02-20 | Aimtron Technology Corp. | Switching voltage regulator operating without a discontinuous mode |
| AU2006239930A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Benzodioxane and benzodioxolane derivatives and uses thereof |
| CN101203505A (zh) | 2005-04-22 | 2008-06-18 | 惠氏公司 | 苯并二氢吡喃和苯并吡喃衍生物及其用途 |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| US7856263B2 (en) | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| AU2006239942A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| CN101203218A (zh) | 2005-04-22 | 2008-06-18 | 惠氏公司 | 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途 |
| AU2006239941A1 (en) | 2005-04-24 | 2006-11-02 | Wyeth | Methods for modulating bladder function |
| EP1893130A4 (en) | 2005-06-17 | 2015-08-26 | Georgia Tech Res Inst | COATED MICROSTRUCTURES AND METHOD FOR THE PRODUCTION THEREOF |
| US20080195035A1 (en) | 2005-06-24 | 2008-08-14 | Frederickson Franklyn L | Collapsible Patch and Method of Application |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| WO2007098945A2 (en) | 2006-03-02 | 2007-09-07 | Ferring International Center S.A. | Stable solid dosage form comprising desmopressin |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| JP5451613B2 (ja) | 2007-08-06 | 2014-03-26 | アラーガン、インコーポレイテッド | デスモプレシン薬物送達のための方法及びデバイス |
| NO3085381T3 (2) * | 2008-05-21 | 2018-09-15 |
-
2009
- 2009-05-21 NO NO16165875A patent/NO3085381T3/no unknown
- 2009-05-21 EP EP17171155.9A patent/EP3225250B1/en active Active
- 2009-05-21 PT PT17171152T patent/PT3225249T/pt unknown
- 2009-05-21 ES ES13181216.6T patent/ES2596435T3/es active Active
- 2009-05-21 EP EP09751584.5A patent/EP2296686B2/en active Active
- 2009-05-21 ES ES17171155T patent/ES2756706T3/es active Active
- 2009-05-21 LT LTEP16165875.2T patent/LT3085381T/lt unknown
- 2009-05-21 CA CA2724653A patent/CA2724653A1/en not_active Abandoned
- 2009-05-21 ES ES16165875.2T patent/ES2677548T3/es active Active
- 2009-05-21 SI SI200932000T patent/SI3225250T1/sl unknown
- 2009-05-21 PT PT161658752T patent/PT3085381T/pt unknown
- 2009-05-21 PL PL09751584T patent/PL2296686T5/pl unknown
- 2009-05-21 NO NO09751584A patent/NO2296686T3/no unknown
- 2009-05-21 PT PT131812166T patent/PT2712622T/pt unknown
- 2009-05-21 PL PL16165875T patent/PL3085381T3/pl unknown
- 2009-05-21 PT PT97515845T patent/PT2296686E/pt unknown
- 2009-05-21 HU HUE16165875A patent/HUE039013T4/hu unknown
- 2009-05-21 TR TR2018/07224T patent/TR201807224T4/tr unknown
- 2009-05-21 DK DK13181216.6T patent/DK2712622T3/en active
- 2009-05-21 HU HUE17171155A patent/HUE046050T2/hu unknown
- 2009-05-21 LT LTEP13181216.6T patent/LT2712622T/lt unknown
- 2009-05-21 DK DK16165875.2T patent/DK3085381T3/en active
- 2009-05-21 HU HUE17171152A patent/HUE041370T2/hu unknown
- 2009-05-21 EP EP16165875.2A patent/EP3085381B1/en active Active
- 2009-05-21 EP EP13181216.6A patent/EP2712622B1/en active Active
- 2009-05-21 DK DK09751584.5T patent/DK2296686T4/en active
- 2009-05-21 ES ES09751584.5T patent/ES2462465T5/es active Active
- 2009-05-21 SI SI200931494A patent/SI2712622T1/sl unknown
- 2009-05-21 ES ES17171152T patent/ES2710454T3/es active Active
- 2009-05-21 HU HUE13181216A patent/HUE030409T2/en unknown
- 2009-05-21 PT PT171711559T patent/PT3225250T/pt unknown
- 2009-05-21 PL PL13181216T patent/PL2712622T3/pl unknown
- 2009-05-21 EP EP17171152.6A patent/EP3225249B1/en active Active
- 2009-05-21 LT LTEP17171152.6T patent/LT3225249T/lt unknown
- 2009-05-21 JP JP2011510705A patent/JP5767103B2/ja active Active
- 2009-05-21 PL PL17171155T patent/PL3225250T3/pl unknown
- 2009-05-21 SI SI200931912T patent/SI3225249T1/sl unknown
- 2009-05-21 SI SI200931838T patent/SI3085381T1/en unknown
- 2009-05-21 PL PL17171152T patent/PL3225249T3/pl unknown
- 2009-05-21 LT LT17171155T patent/LT3225250T/lt unknown
- 2009-05-21 US US12/469,801 patent/US9974826B2/en active Active
- 2009-05-21 TR TR2018/19189T patent/TR201819189T4/tr unknown
- 2009-05-21 WO PCT/US2009/044860 patent/WO2009143356A1/en not_active Ceased
- 2009-05-21 DK DK17171155T patent/DK3225250T3/da active
- 2009-05-21 DK DK17171152.6T patent/DK3225249T3/en active
-
2015
- 2015-03-31 JP JP2015072698A patent/JP6001121B2/ja active Active
-
2016
- 2016-08-22 HR HRP20161066TT patent/HRP20161066T1/hr unknown
- 2016-08-31 JP JP2016169163A patent/JP6258424B2/ja active Active
-
2017
- 2017-01-20 LT LTPA2017001C patent/LTC2712622I2/lt unknown
- 2017-04-12 LU LU00015C patent/LUC00015I2/fr unknown
- 2017-12-06 JP JP2017234382A patent/JP6506821B2/ja active Active
-
2018
- 2018-01-26 US US15/880,697 patent/US20180250357A1/en not_active Abandoned
- 2018-05-17 HR HRP20180774TT patent/HRP20180774T1/hr unknown
-
2019
- 2019-01-18 HR HRP20190114TT patent/HRP20190114T1/hr unknown
- 2019-03-29 JP JP2019067813A patent/JP6836618B2/ja active Active
- 2019-04-26 HU HUS1900024C patent/HUS1900024I1/hu unknown
- 2019-04-30 NO NO2019021C patent/NO2019021I1/no unknown
- 2019-10-14 HR HRP20191854TT patent/HRP20191854T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2596435T3 (es) | Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia | |
| PT2275086E (pt) | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração | |
| BR112012003730A2 (pt) | terapia com acetato de glatirâmer de baixa frequência | |
| CN104284665A (zh) | 吡唑衍生物及其医药用途 | |
| ES2559446T3 (es) | Desmopresina para reducir micciones nocturnas | |
| Torres et al. | Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease | |
| Feuchtbaum et al. | Alvimopan for the reduction of postoperative ileus after long posterior spinal fusion: placebo-controlled double-blind randomized trial | |
| US11963995B2 (en) | Methods comprising desmopressin | |
| Fedele et al. | Effects of medication on parotid salivary flow rates in an individual with dementia of the Alzheimer type | |
| NI | A Randomised Control Trial of Nifedipine Versus Captopril for the Treatment of Hypertension in Children with Acute Post-Streptococcal Glomerulonephritis. | |
| Yoon et al. | Primary mono-symptomatic nocturnal enuresis: A review of management | |
| Farrington | Atomized lidocaine prior to nasogastric tube placement | |
| Ogundipe et al. | Hyponatraemia associated with the use of a proton pump inhibitor | |
| Tennant | Adrenocorticotropin (acth) as a biomarker of uncontrolled pain | |
| Prajapati et al. | Olanzapine Induced Tardive Dystonia | |
| Riley et al. | A 20-Year-Old Female With Polyuria and Polydipsia | |
| Molokie et al. | Predictors of morphine and hydromorphone doses for patients with sickle cell disease in an urban day hospital and emergency department | |
| Emerson | Gastrointestinal Problems Retching, Vomiting, Feeding Intolerance | |
| Pecora et al. | Sertraline-Induced Hyponatremia | |
| Guite et al. | Medication use among pediatric patients with chronic musculoskeletal pain referred for an initial multidisciplinary pain clinic evaluation | |
| HK1228266B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |